Table 2 Registered clinical trials of mitochondria-targeted therapeutics in cancer treatment
From: Mitochondrial metabolism and cancer therapeutic innovation
ClinicalTrials.gov ID | Phase | Start date (year) | Status | Targeted functions | Drugs used | Combination of drugs |
|---|---|---|---|---|---|---|
NCT05680662 | Early Phase 1 | 2023 | Unknown status | ETC inhibitors | Metformin | Quercetin, EGCG, Zinc |
NCT01981525 | Phase 1 | 2014 | Completed | ETC inhibitors | Metformin | Â |
NCT03311308 | Phase 1 | 2018 | Recruiting | ETC inhibitors | Metformin | Pembrolizumab |
NCT05136846 | Phase 1 | 2021 | Recruiting | ETC inhibitors | Papaverine | Carboplatin, Durvalumab |
NCT05759312 | Phase 1/2 | 2023 | Unknown status | ETC inhibitors | Metformin | Zimberelimab |
NCT03709147 | Phase 2 | 2018 | Unknown status | ETC inhibitors | Metformin | Metformin plus/minus Cyclic Fasting Mimicking diet (FMD) |
NCT02874430 | Phase 2 | 2016 | Unknown status | ETC inhibitors | Metformin | Doxycycline |
NCT03675893 | Phase 2 | 2018 | Active, not recruiting | ETC inhibitors | Metformin | Abemaciclib + Letrozole +/ − Metformin or Zotatifin |
NCT04114136 | Phase 2 | 2020 | Recruiting | ETC inhibitors | Metformin | Nivolumab or Pembrolizumab |
NCT04945148 | Phase 2 | 2024 | Recruiting | ETC inhibitors | Metformin | Temozolomide |
NCT03664115 | Phase 2 | 2018 | Unknown status | ETC inhibitors | Itraconazole | Chemotherapy |
NCT02168140 | Phase 1 | 2014 | Completed | TCA cycle | CPI-613 | Bendamustine Hydrochloride |
NCT05325281 | Phase 1 | 2022 | Recruiting | TCA cycle | CPI-613 | Gemcitabine/Intensity-modulated Radiation Therapy |
NCT02232152 | Phase 1 | 2015 | Completed | TCA cycle | CPI-613 | Fluorouracil |
NCT05070104 | Phase 1 | 2023 | Withdrawn | TCA cycle | CPI-613 | Modified FOLFIRINOX + Bevacizumab |
NCT02484391 | Phase 1 | 2015 | Completed | TCA cycle | CPI-613 | Cytarabine |
NCT04732065 | Phase 1 | 2021 | Recruiting | TCA cycle | ONC206 | Â |
NCT02806817 | Early Phase 1 | 2016 | Completed | TCA cycle | ME-344 | Bevacizumab |
NCT06611839 | Phase 1/2 | 2024 | Not yet recruiting | TCA cycle | Ivosidenib | Venetoclax |
NCT03699319 | Phase 1/2 | 2018 | Completed | TCA cycle | CPI-613 | mFOLFIRINOX |
NCT02472626 | Phase 1/2 | 2015 | Withdrawn | TCA cycle | CPI-613 | Cytarabine + Daunorubicin Hydrochloride |
NCT03394027 | Phase 2 | 2018 | Completed | TCA cycle | ONC201 | Â |
NCT03374852 | Phase 2 | 2017 | Withdrawn | TCA cycle | CPI-613 | Mfolfirnox |
NCT02883036 | Observational | 2016 | Unknown status | TCA cycle | Tigecycline | Â |
NCT04109820 | Not Applicable | 2020 | Recruiting | Mitochondrial-targeting antioxidant | MitoQ | Â |
NCT05146843 | Not Applicable | 2021 | Unknown status | Mitochondrial-targeting antioxidant | MitoQ | Â |
NCT04827810 | Phase 1 | 2021 | Suspended | Hsp90 inhibitor | Gamitrinib | Â |
NCT00773747 | Phase 3 | 2008 | Completed | Hsp90 inhibitor | Vorinostat (MK-0683) | Bortezomib |
NCT05381909 | Phase 1 | 2022 | Active, not recruiting | Mitochondrial-derived activator of caspases | BGB-24714 | Paclitaxel, Carboplatin |
NCT04975204 | Phase 1 | 2022 | Unknown status | Mitochondrial-derived activator of caspases | TQB3909 | Â |
NCT05775575 | Phase 1/2 | 2023 | Unknown status | Mitochondrial-derived activator of caspases | TQB3909 | Â |
NCT00566410 | Phase 1 | 2007 | Completed | Pyruvate dehydrogenase kinase inhibitor | Dichloroacetate (DCA) | Â |
NCT04122625 | Phase 1/2 | 2019 | Completed | Second mitochondrial activator of caspases (SMAC) | Debio 1143 | Nivolumab |
NCT03270176 | Phase 1 | 2017 | Completed | Second mitochondrial activator of caspases (SMAC) | Debio 1143 | Avelumab |
NCT02098161 | Phase 2 | 2014 | Completed | Second mitochondrial activator of caspases (SMAC) | LCL161 | Â |
NCT01955434 | Phase 2 | 2013 | Completed | Second mitochondrial activator of caspases (SMAC) | LCL161 | LCL161 alone or with cyclophosphamide |
NCT04651634 | Phase 2 | 2021 | Active, not recruiting | Reactive oxygen species scavenger | MIT-001 | Â |
NCT02071862 | Phase 1 | 2014 | Completed | Glutaminase inhibitor | CB-839 | Â |
NCT02520011 | Phase 2 | 2016 | Terminated | Mitochondrial calcium uniporter | Mitoxantrone | Cytarabine, Alvocidib |
NCT01965834 | Phase 2 | 2012 | Terminated | Fatty acid oxidation | Fenofibrate | Â |
